Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
Sponsor: Cedars-Sinai Medical Center
This PHASE4 trial investigates Abnormalities, Drug-Induced and Long QT Syndrome and is currently completed. Cedars-Sinai Medical Center leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
May 2025 — Present [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE4
▶ Show 7 earlier versions
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE4
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE4
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE4
-
Nov 2021 — Jun 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cedars-Sinai Medical Center
- Harvard University
- Indiana University
- National Heart, Lung, and Blood Institute (NHLBI)
- Purdue University
For direct contact, visit the study record on ClinicalTrials.gov .